AHMED ALSAIF

Dr. AHMED ALSAIF

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2025 in Healthcare
Verified
Journal Article
Open access
PDF file
AAAHMED ALSAIF
AHMED ALSAIF
JAJawad S. Alnajjar
Jawad S. Alnajjar
FAFaisal A. Al-Harbi
Faisal A. Al-Harbi
AAAhmed Awadh S Alsirhani
Ahmed Awadh S Alsirhani
SASultan Salman Alruqaie
Sultan Salman Alruqaie
AAAhmed Y. Azzam
Ahmed Y. Azzam
Background: Inflammatory bowel disease (IBD) represents a growing health challenge in regions undergoing socioeconomic transition. This study characterized IBD epidemiology across Gulf Cooperation Council (GCC) countries, forecasted future burden, and identified country-specific determinants to inform targeted health policy interventions. Methods: IBD data from the Global Burden of Disease study (1990–2021) were analyzed for all six GCC countries using descriptive epidemiology, temporal trend analysis, three forecasting models (Age-Period-Cohort, Joinpoint regression, Bayesian age-standardized rate modeling), and regression analyses to identify socioeconomic, environmental, gender-specific, and healthcare system factors associated with IBD burden variation. Results: Age-standardized IBD prevalence rates varied across GCC countries (28.92–42.93 per 100,000), with Qatar and the United Arab Emirates (UAE) showing the highest rates and fastest increases (967% and 898% since 1990). Kuwait uniquely demonstrated stable or slightly declining trends. Significant female predominance emerged in most countries (male ratio 0.70–0.91) with strong birth cohort effects (1970s cohorts showing 18–48% higher risk than 1950s cohorts). IBD manifested primarily as disability rather than a mortality burden. Projections indicate continued increases through 2030, potentially reaching 55–59 per 100,000 in Qatar and the UAE. Fast food outlet density, processed food imports, antibiotic consumption, and female vitamin D deficiency were the most significant modifiable risk factors. Conclusions: The GCC region faces a growing IBD epidemiological profile characterized by rising burden, female predominance, and generational differences in risk observations. Identification of modifiable determinants provides actionable targets for intervention, while country-specific projections offer a foundation for healthcare planning to address this challenge.

26 November 2025 in Healthcare
Verified
Journal Article
Open access
PDF file
JAJawad S. Alnajjar
Jawad S. Alnajjar
FAFaisal A. Al-Harbi
Faisal A. Al-Harbi
AAAHMED ALSAIF
AHMED ALSAIF
GAGhaida Saleh Alabdulaaly
Ghaida Saleh Alabdulaaly
OAOmar Aljubaili
Omar Aljubaili
AAAhmed Y. Azzam
Ahmed Y. Azzam
Background: Appendiceal neoplasms account for less than 1% of gastrointestinal cancers but are increasing in incidence worldwide. Their marked histological variations and differences create multiple challenges for prognosis and management planning, as current staging systems are limited in certain aspects for capturing the entire disease complexity. Methods: We synthesized data from 18 large observational studies, including 67,001 patients diagnosed between 1973 and 2024. Using advanced computational modeling, we combined multiple statistical methods and machine learning techniques to improve risk stratification, survival prediction, treatment optimization, and forecasting. A novel overlap-aware weighting methodology was applied to prevent double-counting across overlapping registries. Results: Our multi-dimensional risk model outperformed TNM staging (C-index 0.758 vs. 0.689), identifying five prognostic groups with five-year overall survival ranging from 88.7% (low-risk neuroendocrine tumors (NETs)) to 27.3% (high-risk signet-ring cell carcinomas (SRCC)). Hierarchical survival analysis demonstrated marked variation across histological variants, with goblet cell adenocarcinoma showing the most favorable outcomes. Causal inference confirmed the survival benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in stage IV disease (five-year overall survival (OS) 87.4%) and highlighted disparities in outcomes by race and institutional volume. Time-series forecasting projected a 25% to 50% increase in incidence by 2030, highlighting the growing risk of global burden. Conclusions: By integrating multi-database evidence with advanced modeling and statistical methodologies, our findings demonstrate valuable insights and implications for individualized prognosis, better management decision-making, and health system planning. Our proposed approach and demonstrated methodologies are warranting better progression and advancements in precision oncology and utilization of computational modeling techniques in big data as well as digital health progression landscape.

19 June 2026 in Annals of Middle Eastern Medicine
Verified
Journal Article
Closed access
SASara Mahfoud Alghamdi
Sara Mahfoud Alghamdi
MAMohammed A. Alahmadi
Mohammed A. Alahmadi
AAAHMED ALSAIF
AHMED ALSAIF
LALama S Alghamdi
Lama S Alghamdi
SAShahad A Alshehri
Shahad A Alshehri
AAAbdullah Algarni
Abdullah Algarni
Chronic inflammatory skin diseases, including psoriasis and atopic dermatitis, are associated with an increased risk of cardiovascular disease (CVD), largely due to systemic inflammation. Biologic therapies that target key inflammatory cytokines have shown promise not only in improving skin outcomes but also in potentially modifying cardiovascular risk. This study aims to evaluate the impact of biologic treatments used in dermatology on CVD risk through a systematic review and single-arm meta-analysis. Databases including PubMed, Google Scholar, Web of Science, Medline, Scopus, Wiley, EBSCO, and ScienceDirect were searched for studies reporting cardiovascular outcomes in patients receiving biologics for dermatologic conditions. Eligible studies included randomized controlled trials (RCTs), observational cohorts, and case series. Cardiovascular outcomes assessed included major adverse cardiovascular events (MACE), myocardial infarction, stroke, and changes in cardiovascular risk factors. A total of 21 studies were included. The pooled proportion of patients experiencing cardiovascular outcomes after biologic therapy was 7.82% (95% CI: 5.31%–11.37%) under the random-effects model. A modest but significant correlation (r = 0.2051, p = 0.0126) between biologics and cardiovascular benefit was observed. Sensitivity analyses supported the robustness of findings. Risk of bias ranged from low to moderate. Biologic therapies in dermatology, particularly TNF-α, IL-17, and IL-23 inhibitors, may reduce cardiovascular risk through systemic inflammation suppression. However, heterogeneity, publication bias, and a predominance of observational data limit the strength of conclusions. Further RCTs are needed to confirm these findings.

13 October 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
Abdullah AlmaqhawiAbdullah Almaqhawi
Abdullah Almaqhawi
AAAHMED ALSAIF
AHMED ALSAIF
HAHamza Ashraf
Hamza Ashraf
MAMiad Alhamrani
Miad Alhamrani
NANada Khaled Ameen
Nada Khaled Ameen
AAAli Ahmed K Albahrani
Ali Ahmed K Albahrani
Background/Objectives: Dapagliflozin is a foundational chronic heart failure therapy, but whether it retains benefit when initiated early during hospitalization for acute heart failure (AHF) remains uncertain. Methods: We searched MEDLINE, Embase, Scopus, and CENTRAL from inception to 26 January 2026 for randomized trials comparing early initiation of dapagliflozin 10 mg once daily with standard therapy in adults hospitalized for AHF (PROSPERO CRD420261364466). Two reviewers independently performed screening, extraction, and risk-of-bias assessment. Outcomes were pooled under random-effects models with Knapp–Hartung adjustment. Results: Ten trials enrolling 3507 participants (1769 in the dapagliflozin group and 1738 in the control group) were eligible. Dapagliflozin significantly reduced all-cause mortality (RR 0.67, 95% CI 0.52–0.86) and urinary tract infections (RR 0.52, 95% CI 0.35–0.76), while no significant differences were observed in cardiovascular death, MACEs, heart failure hospitalization, all-cause readmission, length of hospital stay, or body weight. Dapagliflozin was not associated with a significant increase in acute kidney injury, hypotension, or hypoglycemia, supporting a favorable safety profile. Conclusions: In adults hospitalized with acute heart failure (AHF), dapagliflozin significantly reduced all-cause mortality but not heart failure hospitalization during follow-up. Larger, adequately powered trials in patients with AHF, with prespecified analyses according to the timing of dapagliflozin initiation, are warranted.

28 August 2026 in American Journal of Therapeutics
Verified
Journal Article
Closed access
MAMohanad A. Alkuwaiti
Mohanad A. Alkuwaiti
FAFaisal A. Al-Harbi
Faisal A. Al-Harbi
FAFeras A. Alkuwaiti
Feras A. Alkuwaiti
AAAHMED ALSAIF
AHMED ALSAIF
HAHamza Ashraf
Hamza Ashraf
Introduction: Infective endocarditis (IE) requires 4 to 6 weeks of intravenous antibiotics. Outpatient parenteral antibiotic therapy (OPAT) is increasingly used and guideline endorsed, but IE-specific comparative evidence is limited, as prior meta-analyses pooled single-arm data without an inpatient comparator. We compared the safety and efficacy of OPAT versus continued hospital-based antibiotic therapy. Methods: This systematic review and meta-analysis followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020. PubMed/MEDLINE, Embase, Cochrane CENTRAL, and Web of Science were searched to 18 April 2026 for comparative studies of adults with IE. Two reviewers screened using Rayyan and extracted data, and risk of bias was assessed with Risk Of Bias In Non-randomized Studies of Interventions. Random-effects meta-analyses (DerSimonian–Laird) produced risk ratios with 95% confidence intervals (CIs) (RevMan 5.4). Results: Five comparative studies (3497 adults) were included. OPAT was associated with lower all-cause mortality (risk ratio [RR]: 0.40, 95% CI: 0.18–0.90; I 2 = 87%, P = 0.03) and with lower acute kidney failure (RR: 0.71, 95% CI: 0.59–0.86, P = 0.0004). No significant differences were seen for readmission (RR: 1.09), relapse (0.73), valve replacement (1.15), arrhythmia, sepsis, stroke, embolic complications, or heart failure. Conclusions: In appropriately selected, stabilized patients, OPAT was associated with lower all-cause mortality and acute kidney failure, with no significant differences in major other adverse events. Protocol: CRD420261410723.

24 August 2026 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
MAMohanad A. Alkuwaiti
Mohanad A. Alkuwaiti
FAFaisal A. Al-Harbi
Faisal A. Al-Harbi
AAAHMED ALSAIF
AHMED ALSAIF
ZAZiyad M. AlSughayyir
Ziyad M. AlSughayyir
RARayan Saleh Alsaud
Rayan Saleh Alsaud
AAAhmed Y. Azzam
Ahmed Y. Azzam